Pureos Bioventures, a St. Peter Port, Guernsey and Zurich, Switzerland-based newly formed venture capital firm, advised by Bellevue Asset Management, closed its first fund BB Pureos Bioventures LP, with committed capital of USD 170m.
The supporters of the first fund include strategic limited partners, such as pharmaceutical and biotech companies as well as a large contract manufacturer, and family offices, institutional investors, and fund-of-funds.
Led by Founding partners Klaus Breiner, Dominik Escher, and Martin Münchbach, Pureos will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell, and gene therapies.
The vehicle invests globally, with a primary focus on Switzerland and Europe. For its first fund, the firm is building a balanced portfolio of 15-20 pre-clinical and clinical-stage companies. Its initial investments include Alentis Therapeutics AG, AM-Pharma BV, Eyevensys SAS, Imcheck Therapeutics SAS, Lava Therapeutics BV, NovaGo Therapeutics AG and Vico Therapeutics BV.
Pureos also is a Partner of BaseLaunch, a start-up accelerator in Basel and together with a team of Entrepreneurs-in-Residence, is working on translating ground-breaking science into novel companies.
FinSMEs
23/09/2020